A few weeks ago, I was speaking with a friend who works in private equity, she told me about a firm that was moving into the 503A compounding pharmacy space, I was intrigued by what it was they were looking to do and how they were going to do it. Given the massive amount of expenses and regulation that are facing the community. I was wondering how these people see themselves partnering with 503As, and whether it was a partnership or an acquisition.

Support the show